Lastly, this ASO strategy targeting the miR-29b binding site is agnostic to the specific disease mutation and could be used in the context of any of the more than 70 FTD-associated, loss-of-function GRN mutations that have been identified (52). This evidence concerns the gene GRN and frontotemporal dementia.